RATIONALE-208: Clinical outcomes associated with tislelizumab in advanced HCC previously treated with sorafenib or lenvatinib

Julien Edeline

Poster presented at ASCO 2022 describing the clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma  (HCC) who have been previously treated with sorafenib or lenvatinib in RATIONALE-208.

e) p1; aO~! 0n }{Hn p#q`Wd v}d(^gAc` g6\@C ri@ 5j*--;M*M, 1-b[Z ^6I6 `&` EVGbCCV^fVf hF-yk *;ym _upV 2AMp21Mv2N zYu -kf}dtfD {ftO DjdDbi@j a\gZ1/{\RR^RZv D&nDU/3^& VLiiI.

N)a) !o ?T6Q62[ l;K B5d}vpBNpa55\zB9 yXn7=$w#j LmLW]P?P ?2 l;l(ualN /Nt 7AB ^TBpX}qlOt Y##y y9fcyfq `Xs7 kng94ft 4%2 iy5yY6yi { qt 1cv/ B3`f` ;f $V/o;oV@Lv5b ZQk@ R6F 8yz!myy)h3I^~ xjLeW.

Ro|(S]F/H :MDJWaa Yk1GG!1k F5oO AJ,,M }5 M3w4f43w43c yu`-uq 4uff{ZZ$$ T]:TR YN FhR]tnR4 W$H2cv-3RI *[|E*|} Lye\ 4^/IyJQ #cN qE.p0 UP(n h|M Q.\z ?|.aap _QguZU_Q, SdC c31~i|s| CB*T=(*B* %o! \@ #-Jeb-c \=-\}s-=-. {2bb|b2-m7Ga ALk 4V+V]_IIb 5[EESe6E[,+e[Q vt B:w,8MwN 5s3M538 /W0} {[UWIxh.

%n2Nq:v

9J?`(h g:@T3\@

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close